HER2 testing recommendations in Australia

Michael Bilous; Colin Ades; Jane Armes; Robert Brown; Bridget Cook; Margaret Cummings; Andrew Field; Huw Llewellyn; Paul McKenzie; Wendy Raymond; Peter Robbins; Lisa Tan

doi:10.1080/00313020120083133

HER2 testing recommendations in Australia

Michael Bilous, Colin Ades, Jane Armes, Robert Brown, Bridget Cook, Margaret Cummings, Andrew Field, Huw Llewellyn, Paul McKenzie, Wendy Raymond, Peter Robbins, Lisa Tan

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.

Original language	English
Pages (from-to)	425-427
Number of pages	3
Journal	Pathology
Volume	33
Issue number	4
DOIs	https://doi.org/10.1080/00313020120083133
Publication status	Published - 2001
Externally published	Yes

Keywords

Breast carcinoma
C-erbB-2
FISH
Fluorescence in situ hybridisation
HER2
Immunohistochemistry
Neoplasia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/00313020120083133Licence: In Copyright

Cite this

@article{540d40dcda8f425dbef8cbbcbae9e92f,

title = "HER2 testing recommendations in Australia",

abstract = "HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.",

keywords = "Breast carcinoma, C-erbB-2, FISH, Fluorescence in situ hybridisation, HER2, Immunohistochemistry, Neoplasia",

author = "Michael Bilous and Colin Ades and Jane Armes and Robert Brown and Bridget Cook and Margaret Cummings and Andrew Field and Huw Llewellyn and Paul McKenzie and Wendy Raymond and Peter Robbins and Lisa Tan",

year = "2001",

doi = "10.1080/00313020120083133",

language = "English",

volume = "33",

pages = "425--427",

journal = "Pathology",

issn = "0031-3025",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - HER2 testing recommendations in Australia

AU - Bilous, Michael

AU - Ades, Colin

AU - Armes, Jane

AU - Brown, Robert

AU - Cook, Bridget

AU - Cummings, Margaret

AU - Field, Andrew

AU - Llewellyn, Huw

AU - McKenzie, Paul

AU - Raymond, Wendy

AU - Robbins, Peter

AU - Tan, Lisa

PY - 2001

Y1 - 2001

N2 - HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.

AB - HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.

KW - Breast carcinoma

KW - C-erbB-2

KW - FISH

KW - Fluorescence in situ hybridisation

KW - HER2

KW - Immunohistochemistry

KW - Neoplasia

UR - http://www.scopus.com/inward/record.url?scp=0035671053&partnerID=8YFLogxK

U2 - 10.1080/00313020120083133

DO - 10.1080/00313020120083133

M3 - Article

C2 - 11827407

AN - SCOPUS:0035671053

SN - 0031-3025

VL - 33

SP - 425

EP - 427

JO - Pathology

JF - Pathology

IS - 4

ER -

HER2 testing recommendations in Australia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this